

Seongman Bae

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/658049/publications.pdf>

Version: 2024-02-01

58
papers

965
citations

567281

15
h-index

501196

28
g-index

59
all docs

59
docs citations

59
times ranked

1485
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled Comparison in 4 Patients. <i>Annals of Internal Medicine</i> , 2020, 173, W22-W23.	3.9	138
2	Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e115.	2.5	111
3	Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals. <i>JAMA Network Open</i> , 2022, 5, e2213606.	5.9	65
4	Factors of Severity in Patients with COVID-19: Cytokine/Chemokine Concentrations, Viral Load, and Antibody Responses. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2412-2418.	1.4	60
5	In Vitro Synergistic Activity of Antimicrobial Agents in Combination against Clinical Isolates of Colistin-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6774-6779.	3.2	59
6	Effectiveness of surgical, KF94, and N95 respirator masks in blocking SARS-CoV-2: a controlled comparison in 7 patients. <i>Infectious Diseases</i> , 2020, 52, 908-912.	2.8	49
7	Association of herpes zoster with dementia and effect of antiviral therapy on dementia: a population-based cohort study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 987-997.	3.2	45
8	Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in South Korea. <i>Journal of Korean Medical Science</i> , 2021, 36, e153.	2.5	45
9	Diagnostic usefulness of subgenomic RNA detection of viable SARS-CoV-2 in patients with COVID-19. <i>Clinical Microbiology and Infection</i> , 2022, 28, 101-106.	6.0	27
10	Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2021, 36, e83.	2.5	24
11	Fluvoxamine Treatment of Patients with Symptomatic COVID-19 in a Community Treatment Center: A Preliminary Result of Randomized Controlled Trial. <i>Infection and Chemotherapy</i> , 2022, 54, 102.	2.3	23
12	Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. <i>Journal of Infectious Diseases</i> , 2022, 225, 777-784.	4.0	21
13	Clinical and Virological Characteristics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) B.1.617.2 (Delta) Variant: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2022, 75, e27-e34.	5.8	20
14	Nosocomial Outbreak of COVID-19 in a Hematologic Ward. <i>Infection and Chemotherapy</i> , 2021, 53, 332.	2.3	19
15	Short versus prolonged courses of antimicrobial therapy for patients with uncomplicated <i>Pseudomonas aeruginosa</i> bloodstream infection: a retrospective study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 223-228.	3.0	19
16	Invasive Pulmonary Aspergillosis in Patients With Severe Fever With Thrombocytopenia Syndrome. <i>Clinical Infectious Diseases</i> , 2020, 70, 1491-1494.	5.8	18
17	SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 395-400.	1.4	18
18	Risk factors for isolation of multi-drug resistant organisms in coronavirus disease 2019 pneumonia: A multicenter study. <i>American Journal of Infection Control</i> , 2021, 49, 1256-1261.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Risk of tuberculosis in patients with cancer treated with immune checkpoint inhibitors: a nationwide observational study. , 2021, 9, e002960.		16
20	Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines. Immune Network, 2021, 21, e29.	3.6	14
21	Dynamics of Viral Shedding and Symptoms in Patients with Asymptomatic or Mild COVID-19. Viruses, 2021, 13, 2133.	3.3	14
22	Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study. Journal of Korean Medical Science, 2022, 37, e134.	2.5	14
23	Transmission Characteristics of SARS-CoV-2 That Hinder Effective Control. Immune Network, 2021, 21, e9.	3.6	13
24	Heterologous ChAdOx1 and Bnt162b2 vaccination induces strong neutralizing antibody responses against SARS-CoV-2 including delta variant with tolerable reactogenicity. Clinical Microbiology and Infection, 2022, 28, 1390.e1-1390.e7.	6.0	13
25	Bedside risk prediction for positive follow-up blood culture in Gram-negative bacilli bacteremia: for whom is follow-up blood culture useful?. Infection, 2022, , 1.	4.7	10
26	Contamination of personal protective equipment by SARS-CoV-2 during routine care of patients with mild COVID-19. Journal of Infection, 2020, 81, e165-e167.	3.3	9
27	Correlation between Reactogenicity and Immunogenicity after the ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccination. Immune Network, 2021, 21, e41.	3.6	8
28	Effects of Recent Use of Renin-Angiotensin System Inhibitors on Mortality of Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2020, 7, ofaa519.	0.9	7
29	Germinal Center-Induced Immunity Is Correlated With Protection Against SARS-CoV-2 Reinfection But Not Lung Damage. Journal of Infectious Diseases, 2021, 224, 1861-1872.	4.0	6
30	Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study. BMC Infectious Diseases, 2016, 16, 252.	2.9	5
31	Frequent Occurrence of SARS-CoV-2 Transmission among Non-close Contacts Exposed to COVID-19 Patients. Journal of Korean Medical Science, 2021, 36, e233.	2.5	5
32	C-reactive protein predicts persistent bacteremia caused by community-acquired methicillin-resistant Staphylococcus aureus strain. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2497-2504.	2.9	5
33	The Detailed Kinetics of Cytomegalovirus-specific T cell Responses after Hematopoietic Stem Cell Transplantation: 1 Year Follow-up Data. Immune Network, 2018, 18, e2.	3.6	4
34	Risk Factors for Mortality in Patients with Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae and Escherichia coli bacteremia. Infection and Chemotherapy, 2021, 53, 528.	2.3	4
35	Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea. Viruses, 2021, 13, 329.	3.3	4
36	Changing characteristics of S. aureus bacteremia caused by PVL-negative, MRSA strain over 11Âyears. Scientific Reports, 2021, 11, 15677.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Molecular diagnosis of <i>Coxiella burnetii</i> in culture negative endocarditis and vascular infection in South Korea. <i>Annals of Medicine</i> , 2021, 53, 2258-2267.	3.8	4
38	Acute T cell-mediated rejection after administration of the BNT162b2 mRNA COVID-19 vaccine in a kidney transplant recipient: a case report. <i>Korean Journal of Transplantation</i> , 2021, 35, 253-256.	0.1	4
39	Delayed local reactions after the first administration of the ChAdOx1 nCoV-19 vaccine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3520-3522.	5.7	3
40	Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without. <i>Journal of Infection</i> , 2021, , .	3.3	3
41	Evaluation of copper alloys for reducing infection by methicillin resistant <i>Staphylococcus aureus</i> and vancomycin resistant <i>Enterococcus faecium</i> in intensive care unit and in vitro. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1204-1210.	1.7	3
42	Comparison of antibody responses after the 1st and 2nd doses of COVID-19 vaccine with those of patients with mild or severe COVID-19. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 455-459.	1.7	3
43	518. Comparing the Mortality of Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S249-S250.	0.9	2
44	Human infection with Seoul orthohantavirus in Korea, 2019. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009168.	3.0	2
45	Risk Factors of Recurrent Infection in Patients with <i>Staphylococcus aureus</i> Bacteremia: a Competing Risk Analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	2
46	Clinical and Microbiological Characteristics of Hospital-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia Caused by a Community-Associated PVL-Negative Strain. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab424.	0.9	1
47	Comparison of the Clinical Outcomes of Patients With Positive Xpert Carba-R Tests for Carbapenemase-Producing Enterobacterales According to Culture Positivity. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab594.	0.9	1
48	In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam at Different Inoculum Sizes of Extended-Spectrum β -Lactam-Resistant Enterobacterales Blood Isolates. <i>Antibiotics</i> , 2021, 10, 1492.	3.7	1
49	Breakthrough infections and waning immune responses with ChAdOx1 nCoV-19 or mRNA vaccine in healthcare workers. <i>Clinical and Translational Medicine</i> , 2022, 12, e804.	4.0	1
50	204. Antagonistic Effect of Colistin on Vancomycin Activity Against Methicillin-Resistant <i>Staphylococcus aureus</i> in in vitro and in vivo Studies. <i>Open Forum Infectious Diseases</i> , 2019, 6, S120-S121.	0.9	0
51	2405. Clinical Characteristics and Prognostic Factors for Extraintestinal Infection Caused by <i>Clostridium difficile</i> : An Analysis of 62 Consecutive Cases. <i>Open Forum Infectious Diseases</i> , 2019, 6, S830-S831.	0.9	0
52	135. Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Bacteremia. <i>Open Forum Infectious Diseases</i> , 2019, 6, S95-S96.	0.9	0
53	2605. Mixed Subpopulation of Hemolytic and Non-Hemolytic Phenotype in Clinical <i>Staphylococcus aureus</i> Blood Isolates. <i>Open Forum Infectious Diseases</i> , 2019, 6, S905-S906.	0.9	0
54	109. Clinical Characteristics and Outcomes of <i>Staphylococcus aureus</i> Bacteremia From a Biliary Source. <i>Open Forum Infectious Diseases</i> , 2019, 6, S86-S86.	0.9	0

#	ARTICLE	IF	CITATIONS
55	1707. Invasive Pulmonary Aspergillosis in Patients with Severe Fever with Thrombocytopenia Syndrome. Open Forum Infectious Diseases, 2019, 6, S625-S626.	0.9	0
56	Transient global amnesia associated with toxocariasis and secondary hypereosinophilia. Allergy Asthma & Respiratory Disease, 2016, 4, 217.	0.2	0
57	Kinetics of Glycoprotein-Specific Antibody Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses, 2022, 14, 256.	3.3	0
58	61. Short- versus prolonged-courses of antimicrobial therapy for patients with uncomplicated <i>Pseudomonas aeruginosa</i> bloodstream infection. Open Forum Infectious Diseases, 2021, 8, S41-S42.	0.9	0